Physician profile
Arslan Babar
NPI 1720501182
$1,262.80
in general payments reported to CMS, 2019-2025
12 companies · $246 in 2025
The $246 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $208 · 2020: $128 · 2021: $13.72 · 2022: $19.27 · 2023: $243 · 2024: $405 · 2025: $246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $893.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $217.57 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $176.71 | 2019-2020 | |
| Boston Scientific Corporation | $174.66 | 2024 | Varithena Administration Pack |
| Genzyme Corporation | $149.99 | 2023 | |
| Janssen Biotech, INC. | $139.93 | 2022-2025 | Erleada |
| Adc Therapeutics America, INC. | $121.17 | 2024 | |
| Sanofi-Aventis U.S. LLC | $109.41 | 2024 | |
| Allergan, INC. | $83.22 | 2019-2020 | |
| Insmed, INC. | $44.64 | 2020-2021 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.91 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $12.04 | 2019 | |
| Pfizer INC. | $11.55 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arslan Babar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.